Literature DB >> 2791372

Symptomatology and quality of life in patients with rate-responsive pacemakers: a double-blind, randomized, crossover study.

C P Lau1, J Rushby, M Leigh-Jones, C Y Tam, J Poloniecki, A Ingram, R Sutton, A J Camm.   

Abstract

Although the hemodynamic advantages of rate-responsive (RR) pacing are well established, the symptomatic benefits remain controversial and the effects on the quality of life have not been assessed. Sixteen patients with RR pacemakers and a mean age of 56 (range 22-77) years were involved in a double-blind crossover study to assess their exercise capacity (treadmill testing), symptomatology, and quality of life (structured questionnaires). Pacemakers were implanted because of symptomatic heart block or sick sinus syndrome. Ventricular demand pacemakers were randomly programmed into the constant rate (VVI) or RR pacing modes for four-week study periods. All patients exercised longer in the RR mode than in the VVI mode (570 +/- 29 vs. 437 +/- 17 s, p less than 0.001). Statistically significant improvements in "shortness of breath" and "energy during daily activities" as measured by a 10-point scale were reported in the RR pacing mode by the patients and were also observed by their close relatives. Symptoms such as "chest pain" and "palpitations" were not worsened during RR pacing. Nondisease-specific "quality of life" was studied in 11 patients using the Nottingham Health Profile which showed a trend for an improved quality of life in five of the six dimensions of perceived health, although none of the changes were statistically significant. This study suggests that RR pacing should be recommended in selected patients on symptomatic grounds.

Entities:  

Mesh:

Year:  1989        PMID: 2791372     DOI: 10.1002/clc.4960120907

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  6 in total

1.  Nonpharmacological Treatment of Atrial Fibrillation: What Is the Role of Device Therapy?

Authors:  Lucie Riedlbauchová; Václav Durdil; Jakub Honěk; Josef Veselka
Journal:  Int J Angiol       Date:  2020-04-28

2.  Validating optimal function of the closed loop stimulation sensor with high right septal ventricular electrode placement in 'ablate and pace' patients.

Authors:  John Silberbauer; Paul S G Hong; Rick A Veasey; Nadeem A Maddekar; Wasing Taggu; Nikhil R Patel; Guy W Lloyd; Neil Sulke
Journal:  J Interv Card Electrophysiol       Date:  2009-07-23       Impact factor: 1.900

3.  Cardiac pacing for bradyarrhythmias in the elderly.

Authors:  R Sutton
Journal:  J R Soc Med       Date:  1994-04       Impact factor: 5.344

4.  Oxygen uptake kinetics during low intensity exercise: relevance for rate adaptive pacemaker programming.

Authors:  T Lewalter; H Rickli; D MacCarter; W Jung; R Schimpf; P Schwartze; R Candinas; B Lüderitz
Journal:  Heart       Date:  1997-02       Impact factor: 5.994

5.  2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing.

Authors:  Bruce L Wilkoff; Laurent Fauchier; Martin K Stiles; Carlos A Morillo; Sana M Al-Khatib; Jesœs Almendral; Luis Aguinaga; Ronald D Berger; Alejandro Cuesta; James P Daubert; Sergio Dubner; Kenneth A Ellenbogen; N A Mark Estes; Guilherme Fenelon; Fermin C Garcia; Maurizio Gasparini; David E Haines; Jeff S Healey; Jodie L Hurtwitz; Roberto Keegan; Christof Kolb; Karl-Heinz Kuck; Germanas Marinskis; Martino Martinelli; Mark McGuire; Luis G Molina; Ken Okumura; Alessandro Proclemer; Andrea M Russo; Jagmeet P Singh; Charles D Swerdlow; Wee Siong Teo; William Uribe; Sami Viskin; Chun-Chieh Wang; Shu Zhang
Journal:  J Arrhythm       Date:  2016-02-01

6.  Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial.

Authors:  Maria F Paton; John Gierula; Judith E Lowry; David A Cairns; Kieran Bose Rosling; Charlotte A Cole; Melanie McGinlay; Sam Straw; Rowena Byrom; Richard M Cubbon; Mark T Kearney; Klaus K Witte
Journal:  PLoS One       Date:  2021-12-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.